A study of fostamatinib in subjects with impaired hepatic (liver) function

Study identifier:D4300C00010

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

An Open-label, Single-center Study to Assess the Pharmacokinetics of R406 in Subjects with Hepatic Impairment and in Healthy Subjects Following Administration of a Single Dose of Fostamatinib Disodium 150 mg

Medical condition

Hepatic Impairment, Healthy Volunteers, Amount of R406 in blood

Phase

Phase 1

Healthy volunteers

Yes

Study drug

Fostamatinib

Sex

All

Actual Enrollment

32

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 Oct 2010
Primary Completion Date: 01 Jun 2011
Study Completion Date: 01 Jun 2011

Study design

Allocation: Non-randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Basic Science

Verification:

Verified 01 Apr 2014 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria